Silvia Marchianò, Michele Biagioli, Martina Bordoni, Elva Morretta, Cristina Di Giorgio, Valentina Vellecco, Rosalinda Roselli, Rachele Bellini, Carmen Massa, Luigi Cari, Ginevra Urbani, Patrizia Ricci, Maria Chiara Monti, Antonino Giordano, Vincenzo Brancaleone, Mariarosaria Bucci, Angela Zampella, Eleonora Distrutti, Enrico Cieri, Giuseppe Cirino, Stefano Fiorucci
BACKGROUND: Patients with nonalcoholic fatty liver disease are at increased risk to develop atherosclerotic cardiovascular diseases. FXR and GPBAR1 are 2 bile acid-activated receptors exploited in the treatment of nonalcoholic fatty liver disease: whether dual GPBAR1/FXR agonists synergize with statins in the treatment of the liver and cardiovascular components of nonalcoholic fatty liver disease is unknown. METHODS AND RESULTS: Investigations of human aortic samples obtained from patients who underwent surgery for aortic aneurysms and Gpbar1 -/- , Fxr -/- , and dual Gpbar1 -/- Fxr -/- mice demonstrated that GPBAR1 and FXR are expressed in the aortic wall and regulate endothelial cell/macrophage interactions...
November 23, 2023: Journal of the American Heart Association